BBIO News and Press, BridgeBio Pharma Inc. From 09/06/23

- BridgeBio completed an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), and a scientific advice engagement with the European Union (EU) European Medicines Agency (EMA) - FDA and EMA alignment was reached on the adequacy of a one-year, 2:1 randomized, placebo-co...

2023-08-30 16:08:00 ET Summary BridgeBio's shares have soared by over 150% since the positive results of its drug Acoramidis for treating ATTR-CM were released in July. The final data from the Phase 3 study of Acoramidis confirmed its positive results, and the company plans to sub...

- The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consistently favored acoramidis treatment across key subgroups, including across both variant and wild-type ATTR patients as well as across New Yo...

PALO ALTO, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that detailed Phase 3 results from ATTR...

BridgeBio Pharma, Inc. (NASDAQ: BBIO) is the focus of IBN's latest stock spotlight. The company's shares have moved 3.2% on the day to $29.32. BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 ...

2023-08-15 11:40:24 ET Summary Generating high yields while taking on less market risk is possible. Our Advanced cash covered put selling strategy can generate high double-digit yields with being very conservative with risk. I believe that selling put options capitalizes on ma...

2023-08-14 07:00:00 ET Summary Biotech stocks faced challenges in the first half of the year, with the Nasdaq Biotechnology Index losing 3%, compared to strong advances in the broader market. The direction of the 10-year bond yield has become a key predictor of biotech industry pe...

2023-08-09 10:07:00 ET Wall Street can sometimes wax enthusiastic over young biotechs -- perhaps too much so. That may be the case right now with Palo Alto-based BridgeBio Pharma (NASDAQ: BBIO) , which analysts' consensus estimates predict will see its shares increase by 46% within ...

2023-08-03 10:24:48 ET BridgeBio Pharma press release ( NASDAQ: BBIO ): Q2 GAAP EPS of -$0.98. Revenue of $1.6M. For further details see: BridgeBio Pharma GAAP EPS of -$0.98, revenue of $1.6M

- Announced consistently positive results from the Phase 3 ATTRibute-CM study of acoramidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), including a highly statistically significant result observed on the primary endpoint with a Win Ratio of 1.8 (p<0.0001) and clinically me...